Core Viewpoint - Kanghong Pharmaceutical has shown a positive stock performance with a year-to-date increase of 13.65% and a market capitalization of 31.38 billion yuan as of January 9 [1]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical achieved a revenue of 3.624 billion yuan, representing a year-on-year growth of 6.23%. The net profit attributable to shareholders was 1.033 billion yuan, with a year-on-year increase of 6.08% [2]. Shareholder Information - As of December 31, the number of shareholders for Kanghong Pharmaceutical reached 28,900, an increase of 1.32% from the previous period. The average number of circulating shares per shareholder decreased by 1.30% to 23,805 shares [2]. Dividend Distribution - Since its A-share listing, Kanghong Pharmaceutical has distributed a total of 2.038 billion yuan in dividends, with 1.04 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 28.007 million shares, an increase of 730,000 shares from the previous period. Other notable shareholders include Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A, which saw reductions in their holdings [3].

【#苹果回应房颤记录医疗器械获批# 】近日，国家药品监督管理局批准苹果公司"移动脉率房颤迹象记 录软件"获得"进口医疗器械（注册）第二类"资质。据悉，国家药品监督管理局公示页面显示，移动脉 率房颤迹象记录软件（Atrial Fibrillation History Feature）已于2025年12月26日获批。苹果这款产品由手 表端与手机端组成，属于第二类医疗器械。对此，苹果公司回应媒体表示"近期已获得经国家药品监督 管理局批准的移动脉率房颤迹象记录软件的医疗器械注册证（国械注进20252210606）。正在按照正规 流程办理相关手续。"#苹果手表新功能房颤历史获药监局批准# @共富财经 ...

1月9日，海思科盘中上涨2.09%，截至09:54，报56.15元/股，成交2845.23万元，换手率0.11%，总市值 628.83亿元。 资金流向方面，主力资金净流入191.84万元，特大单买入344.86万元，占比12.12%，卖出135.88万元， 占比4.78%；大单买入412.94万元，占比14.51%，卖出430.08万元，占比15.12%。 海思科今年以来股价涨9.41%，近5个交易日涨9.41%，近20日跌3.98%，近60日涨8.13%。 截至9月30日，海思科股东户数1.29万，较上期增加12.87%；人均流通股37342股，较上期减少11.40%。 2025年1月-9月，海思科实现营业收入33.00亿元，同比增长19.95%；归母净利润2.95亿元，同比减少 22.66%。 分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年9月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2139.75万股，相比上期增加12.12万股。香港中央结算有限公司位居第六大流通股 东，持股1806.01万股 ...

来源：新浪证券-红岸工作室 1月8日，超研股份涨5.15%，成交额1.66亿元，换手率12.02%，总市值101.51亿元。 异动分析 宠物经济+医疗器械概念+水利+人民币贬值受益+注册制次新股 1、2025年3月8日官微：SIUI于3月3日至5日参加了第97届WVC年会。在此次盛会上，SIUI展出了我们 在宠物、马匹和家畜方面的创新兽用医学影像成果，与行业专家就动物医疗保健的发展进行了交流，并 在与一线从业者的交流中获得了宝贵的用户见解。 2、汕头市超声仪器研究所股份有限公司的主营业务是从事医学影像设备、工业无损检测设备的研发、 生产和销售；公司主要产品包括掌上式无线彩超、便携式彩超、推车式彩超、全容积乳腺超声成像系 统、全数字超声显像诊断仪、便携式X射线机、便携式数字化X射线摄影系统、数字超声探伤仪、超声 成像检测仪、自动检测装置和探头、医用超声探头、工业无损检测探头； 5、汕头市超声仪器研究所股份有限公司于2025-01-22日上市，主营业务为医学影像设备、工业无损检 测设备的研发、生产和销售。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入1 ...

甘李药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：中盘、融资融券、 基金重仓、医疗器械、多肽药等。 截至9月30日，甘李药业股东户数9.47万，较上期增加22.53%；人均流通股5889股，较上期减少 17.81%。2025年1月-9月，甘李药业实现营业收入30.47亿元，同比增长35.73%；归母净利润8.18亿元， 同比增长61.32%。 分红方面，甘李药业A股上市后累计派现16.12亿元。近三年，累计派现10.18亿元。 1月8日，甘李药业盘中下跌2.04%，截至14:17，报70.03元/股，成交4.71亿元，换手率1.19%，总市值 418.29亿元。 资金流向方面，主力资金净流出1526.78万元，特大单买入1465.26万元，占比3.11%，卖出3268.39万 元，占比6.94%；大单买入1.24亿元，占比26.34%，卖出1.21亿元，占比25.75%。 甘李药业今年以来股价涨2.88%，近5个交易日涨4.58%，近20日涨10.42%，近60日涨1.20%。 资料显示，甘李药业股份有限公司位于北京市通州区漷县镇南凤西一路8号，成立日期1998年6月17日， 上市日 ...

Company Overview - Aomei Medical is located in Zhijiang, Hubei Province, and was established on July 24, 2002. The company went public on March 11, 2019. Its main business involves the research, production, and sales of disposable medical consumables, including medical dressings [1]. - The revenue composition of Aomei Medical includes: surgical and wound care (79.19%), other categories (6.62%), infection protection (5.05%), advanced dressings (4.68%), and hygiene care (4.46%) [1]. Financial Performance - As of September 30, 2025, Aomei Medical achieved a revenue of 2.597 billion yuan, representing a year-on-year growth of 5.98%. The net profit attributable to the parent company was 349 million yuan, reflecting a year-on-year increase of 31.54% [2]. - Since its A-share listing, Aomei Medical has distributed a total of 1.099 billion yuan in dividends, with 91.913 million yuan distributed over the past three years [3]. Stock Performance - On January 8, Aomei Medical's stock price increased by 2.32%, reaching 11.46 yuan per share, with a trading volume of 50.793 million yuan and a turnover rate of 1.00%. The total market capitalization is 7.257 billion yuan [1]. - Year-to-date, Aomei Medical's stock has risen by 4.95%, with a 5-day increase of 5.04%, a 20-day increase of 0.79%, and a 60-day increase of 18.76% [1]. Shareholder Information - As of September 30, 2025, Aomei Medical had 37,800 shareholders, an increase of 0.71% from the previous period. The average number of circulating shares per person decreased by 0.71% to 11,965 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest, holding 17.9166 million shares, an increase of 5.5221 million shares from the previous period. The Medical Device ETF (159883) is the tenth largest shareholder, holding 1.5656 million shares as a new shareholder [3].

爱美客今年以来股价涨4.61%，近5个交易日涨4.96%，近20日涨5.01%，近60日跌15.52%。 分红方面，爱美客A股上市后累计派现38.87亿元。近三年，累计派现30.12亿元。 资金流向方面，主力资金净流入1392.40万元，特大单买入3670.19万元，占比11.66%，卖出2429.69万 元，占比7.72%；大单买入8204.36万元，占比26.06%，卖出8052.47万元，占比25.57%。 资料显示，爱美客技术发展股份有限公司位于北京市朝阳区建国路甲92号世茂大厦C座21层，成立日期 2004年6月9日，上市日期2020年9月28日，公司主营业务涉及从事生物医用软组织修复材料的研发、生 产和销售。主营业务收入构成为：溶液类注射产品57.27%，凝胶类注射产品37.97%，其他3.01%，冻干 粉类注射产品1.50%，面部埋植线0.26%。 爱美客所属申万行业为：美容护理-医疗美容-医美耗材。所属概念板块包括：合成生物、多肽药、医疗 器械、化妆品、中盘等。 截至12月31日，爱美客股东户数6.01万，较上期减少2.71%；人均流通股3472股，较上期增加2.78%。 2025年1月-9月 ...

Group 1 - The core viewpoint of the news is that Guanhao Biological has shown significant stock price performance and financial metrics, indicating potential growth and investment interest [1][2]. - As of January 8, Guanhao Biological's stock price increased by 22.82% year-to-date, with a market capitalization of 4.51 billion yuan [1]. - The company reported a revenue of 293 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 5.52%, while the net profit attributable to shareholders decreased by 4.02% to 26.72 million yuan [2]. Group 2 - Guanhao Biological's main business segments include medical devices (73.28% of revenue), pharmaceuticals (15.21%), and leasing and other services (11.51%) [1]. - The company has a total of 27,800 shareholders as of December 31, with an average of 9,545 circulating shares per shareholder, indicating a slight increase in shareholding concentration [2]. - The company has distributed a total of 86.66 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

1月8日，迪安诊断盘中上涨2.04%，截至09:54，报17.49元/股，成交9771.20万元，换手率1.13%，总市 值109.31亿元。 资金流向方面，主力资金净流出130.59万元，特大单买入104.21万元，占比1.07%，卖出463.49万元，占 比4.74%；大单买入2044.16万元，占比20.92%，卖出1815.46万元，占比18.58%。 分红方面，迪安诊断A股上市后累计派现10.99亿元。近三年，累计派现7.12亿元。 机构持仓方面，截止2025年9月30日，迪安诊断十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1056.35万股，相比上期减少423.50万股。南方中证1000ETF（512100）位居第七大流通股 东，持股456.88万股，相比上期减少4.09万股。医疗器械ETF（159883）位居第十大流通股东，持股 308.75万股，为新进股东。招商优势企业混合A（217021）、长城消费增值混合A（200006）退出十大 流通股东之列。 责任编辑：小浪快报 资料显示，迪安诊断技术集团股份有限公司位于浙江省杭州市西湖区金蓬街329号2幢5层，成立日期 2001年9 ...

Core Viewpoint - Aidi Te's stock price has shown fluctuations with a recent decline, while the company has experienced overall growth in revenue and profit year-to-date. Group 1: Stock Performance - On January 8, Aidi Te's stock price decreased by 2.09%, reaching 47.78 yuan per share, with a trading volume of 23.93 million yuan and a turnover rate of 0.69%, resulting in a total market capitalization of 5.09 billion yuan [1] - Year-to-date, Aidi Te's stock price has increased by 8.10%, with a 7.03% rise over the last five trading days, 9.44% over the last 20 days, and 10.02% over the last 60 days [2] Group 2: Company Overview - Aidi Te (Qinhuangdao) Technology Co., Ltd. is located in Qinhuangdao, Hebei Province, established on March 15, 2007, and is set to be listed on June 26, 2024 [2] - The company's main business involves the independent research, production, and sales of internationally competitive zirconia ceramic blocks and other dental restoration materials, with revenue composition as follows: dental restoration materials 73.74%, dental digital equipment 19.80%, and other products and services 6.46% [2] - Aidi Te belongs to the Shenwan industry classification of pharmaceutical biology - medical devices - medical consumables, and is associated with concepts such as medical devices, Alibaba concept, small-cap, margin financing, and specialized and innovative [2] Group 3: Financial Performance - As of September 30, Aidi Te had 9,851 shareholders, an increase of 4.66% from the previous period, with an average of 7,310 circulating shares per person, a decrease of 4.46% [2] - For the period from January to September 2025, Aidi Te achieved operating revenue of 747 million yuan, a year-on-year increase of 16.44%, and a net profit attributable to the parent company of 142 million yuan, a year-on-year increase of 27.40% [2] Group 4: Dividend Information - Aidi Te has distributed a total of 49.48 million yuan in dividends since its A-share listing [3]